DK3310331T3 - Injicerbare farmaceutiske formuleringer af lefamulin - Google Patents

Injicerbare farmaceutiske formuleringer af lefamulin Download PDF

Info

Publication number
DK3310331T3
DK3310331T3 DK16729258.0T DK16729258T DK3310331T3 DK 3310331 T3 DK3310331 T3 DK 3310331T3 DK 16729258 T DK16729258 T DK 16729258T DK 3310331 T3 DK3310331 T3 DK 3310331T3
Authority
DK
Denmark
Prior art keywords
lefamulin
pharmaceutical formulations
injectable pharmaceutical
injectable
formulations
Prior art date
Application number
DK16729258.0T
Other languages
English (en)
Inventor
Mathias Ferencic
Werner Heilmayer
Peter Hinsmann
Wolfgang Wicha
Original Assignee
Nabriva Therapeutics GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nabriva Therapeutics GmbH filed Critical Nabriva Therapeutics GmbH
Application granted granted Critical
Publication of DK3310331T3 publication Critical patent/DK3310331T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK16729258.0T 2015-06-17 2016-06-14 Injicerbare farmaceutiske formuleringer af lefamulin DK3310331T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562180871P 2015-06-17 2015-06-17
PCT/EP2016/063609 WO2016202788A1 (en) 2015-06-17 2016-06-14 Injectable pharmaceutical formulations of lefamulin

Publications (1)

Publication Number Publication Date
DK3310331T3 true DK3310331T3 (da) 2021-01-11

Family

ID=56131530

Family Applications (1)

Application Number Title Priority Date Filing Date
DK16729258.0T DK3310331T3 (da) 2015-06-17 2016-06-14 Injicerbare farmaceutiske formuleringer af lefamulin

Country Status (27)

Country Link
US (1) US20180360966A1 (da)
EP (1) EP3310331B1 (da)
JP (1) JP6818019B2 (da)
KR (1) KR102656841B1 (da)
CN (1) CN107810000B (da)
AU (1) AU2016278774C1 (da)
BR (1) BR112017026904B1 (da)
CA (1) CA2989372C (da)
CY (1) CY1123722T1 (da)
DK (1) DK3310331T3 (da)
EA (1) EA033988B1 (da)
ES (1) ES2843723T3 (da)
HK (1) HK1252534A1 (da)
HR (1) HRP20210010T1 (da)
HU (1) HUE053024T2 (da)
IL (1) IL256115A (da)
LT (1) LT3310331T (da)
MX (1) MX2017015812A (da)
PH (1) PH12017502319A1 (da)
PL (1) PL3310331T3 (da)
PT (1) PT3310331T (da)
RS (1) RS61327B1 (da)
SI (1) SI3310331T1 (da)
TW (1) TWI718158B (da)
UA (1) UA121240C2 (da)
WO (1) WO2016202788A1 (da)
ZA (1) ZA201707998B (da)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230218558A1 (en) 2020-04-17 2023-07-13 Nabriva Therapeutics GmbH Novel therapeutic use of pleuromutilins
CN115443131A (zh) 2020-04-17 2022-12-06 纳布里瓦治疗有限责任公司 截短侧耳素类化合物的治疗用途
CN117677709A (zh) * 2021-07-19 2024-03-08 Jbs科学有限公司 从尿液样品中分离循环dna的方法
WO2023152115A1 (en) 2022-02-09 2023-08-17 Nabriva Therapeutics GmbH Lefamulin and its derivatives for use in the treatment of a spiral shaped bacteria
EP4338732A1 (en) 2022-09-16 2024-03-20 Nabriva Therapeutics GMBH Lefamulin and its derivatives for use in the treatment of tularemia

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2011063C (en) * 1989-02-28 1999-07-06 Calum B. Macfarlane Nicardipine pharmaceutical composition for parenteral administration
FR2772272B1 (fr) 1997-12-16 2000-01-14 Rhone Poulenc Rorer Sa Compositions pharmaceutiques a base de dalfopristine et de quinupristine et leur preparation
ATE437860T1 (de) * 2000-04-04 2009-08-15 Smithkline Beecham Plc 2-hydroxy-mutilin-carbamat derivate und ihre anwendung als antibakterielle mittel
GB0308114D0 (en) * 2003-04-08 2003-05-14 Glaxo Group Ltd Novel compounds
JP5507049B2 (ja) * 2004-12-30 2014-05-28 アステックス、セラピューティックス、リミテッド 医薬品
EP2298733B1 (en) * 2005-06-27 2016-05-25 Nabriva Therapeutics AG Pleuromutilin derivatives containing a hydroxyamino- or acyloxyaminocycloalkyl group
EP1972618A1 (en) * 2007-03-20 2008-09-24 Nabriva Therapeutics AG Pleuromutilin derivatives for the treatment of diseases mediated by microbes
US20100331812A1 (en) * 2009-06-29 2010-12-30 Nitric Biotherapeutics, Inc. Pharmaceutical Formulations for Iontophoretic Delivery of an Immunomodulator
EP2399904A1 (en) * 2010-05-26 2011-12-28 Nabriva Therapeutics AG Process for the preparation of pleuromutilins
CN103204787B (zh) * 2012-01-17 2014-10-01 北京艾百诺科技有限公司 含有取代方酸的乙酸妙林酯及其应用
CN103626693B (zh) * 2012-08-28 2016-09-14 中国科学院上海药物研究所 一类截短侧耳素衍生物、其药物组合物及其合成方法与用途
AU2014273471B2 (en) * 2013-05-28 2019-10-03 Morphochem Aktiengesellschaft Fur Kombinatorische Chemie Combination therapy comprising oxazolidinone-quinolones for use in treating bacterial infections

Also Published As

Publication number Publication date
UA121240C2 (uk) 2020-04-27
EA201890075A1 (ru) 2018-05-31
CA2989372C (en) 2023-10-03
US20180360966A1 (en) 2018-12-20
ZA201707998B (en) 2021-04-28
CN107810000A (zh) 2018-03-16
BR112017026904B1 (pt) 2023-10-10
EP3310331A1 (en) 2018-04-25
CN107810000B (zh) 2021-03-12
TW201716056A (zh) 2017-05-16
PT3310331T (pt) 2021-01-19
WO2016202788A1 (en) 2016-12-22
AU2016278774A1 (en) 2017-12-07
HRP20210010T1 (hr) 2021-03-05
EP3310331B1 (en) 2020-10-14
MX2017015812A (es) 2018-07-06
EA033988B1 (ru) 2019-12-17
IL256115A (en) 2018-02-28
AU2016278774B2 (en) 2021-07-29
PL3310331T3 (pl) 2021-04-19
TWI718158B (zh) 2021-02-11
HUE053024T2 (hu) 2021-06-28
CY1123722T1 (el) 2022-05-27
JP2018517777A (ja) 2018-07-05
HK1252534A1 (zh) 2019-05-31
AU2016278774C1 (en) 2021-11-18
LT3310331T (lt) 2021-01-11
JP6818019B2 (ja) 2021-01-20
CA2989372A1 (en) 2016-12-22
KR102656841B1 (ko) 2024-04-12
PH12017502319A1 (en) 2018-06-25
SI3310331T1 (sl) 2021-02-26
ES2843723T3 (es) 2021-07-20
RS61327B1 (sr) 2021-02-26
KR20180030479A (ko) 2018-03-23
BR112017026904A2 (pt) 2018-08-14

Similar Documents

Publication Publication Date Title
DK3529248T3 (da) Farmaceutiske sammensætninger
DK3302565T3 (da) Faste doseringsformer af palbociclib
DK3244948T3 (da) Bestemmelse af medikamentdosis
DK3236943T3 (da) Sammensætninger til ileo-jejunal lægemiddeladministration
DK3089741T3 (da) Farmaceutiske sammensætninger omfattende azd9291
DK3509581T3 (da) Formuleringer af (r)-2-amino-3-phenylpropylcarbamat
DK3116491T3 (da) Farmaceutiske sammensætninger af terapeutisk aktive forbindelser
DK3185853T3 (da) Inhalerbare pulverformuleringer af alginatoligomerer
DK3237045T3 (da) Indretning til indgivelse af lægemidler
BR112018000054A2 (pt) composições farmacêuticas liofilizadas
DK3261608T3 (da) Sammensætninger omfattende kombinationer af organiske syrer
DK3821905T3 (da) Insulin indeholdende farmaceutiske sammensætninger
DK3368044T3 (da) Behandling af hepatisk steatose-relateret oligo-ovulation
HK1252534A1 (zh) 來氟米林的可注射藥物組合物
DK3297619T3 (da) Terapeutiske anvendelser af L-4-chlorkynurenin
ES2969514T3 (es) Composición farmacéutica de liberación sostenida
DK3191085T3 (da) Misbrugsresistente farmaceutiske sammensætninger
DK3418273T3 (da) Derivater af flavagliner
DK3280447T3 (da) Farmaceutiske formuleringer
DK3678644T3 (da) Formuleringer af copanlisib
DK3173071T3 (da) Formularing af maropitant
DK3313370T3 (da) Oftalmologisk farmaceutisk sammensætning
DK3435980T3 (da) Fysiologisk afbalancerede injicerbare formuleringer af fosnetupitant
MA43166A (fr) Formulation de fviii
DK3256138T3 (da) Farmaceutiske sammensætninger omfattende meloxicam